Research Article
BibTex RIS Cite

No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease

Year 2018, Volume: 12 Issue: 2, 25 - 27, 25.09.2018

Ergun Pinarbasi Nilgun Cekin Aslihan Esra Bildirici Mehmet Bakir Serdal Arslan

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne, viral disease that causes severe outbreaks in people throughout large geographical areas. The common feature of viral hemorrhagic fever (VHF) cases is the attack on the cells that initiate the antiviral response and the impaired immune response of the host. There is no study of the variation of the promoter region of Foxp3 gene, which has been shown to be involved in inflammation in studies of autoimmune diseases, in relation to the risk or susceptibility of disease in CCHF patients. Therefore, the aim of our study was to investigate Foxp3 rs3761548 and rs2232365 gene polymorphisms in patients with CCHF. Blood samples taken from 80 CCHF patients and 80 healthy subjects were used in the study. Genotyping was performed by PCR-RFLP followed by total DNA isolation. No statistically significant relationship between Foxp3 gene polymorphisms rs2232365 and rs3761548 and CCHF was found.Although the pathophysiology of CCHF is still not fully understood, there are some mechanisms shown to be related to the immune system. Studies examining other variants in the Foxp3 gene promoter region and of exon and intron mutations may yield beneficial results in terms of the association between gene and disease progression.

Keywords

Crimean-Congo hemorrhagic fever Foxp3 polymorphism

References

  • Elaldı N. 2004. Kırım-Kongo hemorajik ateş epidemiyolojisi. C.Ü. Tıp Fakültesi Dergisi, 26(4):185-190.
  • Ergonul O. 2006. Crimean-Congohaemorrhagicfever. LancetInfect. Dis.,6:203-214.
  • Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, Carroll MW. 2014. A novelvaccineagainstCrimean-Congohaemorrhagicfeverprotects 100% of animalsagainstlethalchallenge in a Mouse model. PlosOne, 9(3):e91516.
  • Leblebicioglu H, Ozaras R, Irmak H, Sencan I. 2016. Crimean-Congohaemorrhagicfever in Turkey: Currentstatus and futurechallenges. Antiviral Research, 126:21-34.
  • Ministry of Health, Turkey. Reports of thecommunicablediseasesdepartment (2008) Ankara (Turkey) (in Turkish). Available at: http://www.saglik.gov.tr
  • Ozkurt Z. 2007. Kırım-Kongo kanamalı ateşi. Yoğun Bakım Dergisi, 7(1):85-90.
  • Elaldi N, Kaya S. 2014. Crimean-Congohaemorrhagicfever. JMID, 1:1-9.
  • Esen F. 2008. CD4+T hücrelerinde güncel gelişmeler: Th17 hücreleri. Cerrahpaşa Öğrenci Bilimsel Dergisi, 1(1).
  • Weaver CT, Harrington LE, Mangan PR, Gavrielli M, Murphy KM. 2006. Th17: An effector CD4 T celllineagewithregulatory T cellties. Immunity, 24:677-688.
  • Oda JMM, Hirata BKB, Guembarovski RL, Watanabe MAE. 2013. Geneticpolymorphism in Foxp3 gene: imbalance in regulatory T cell role and development of humandiseases. J Genet.,92:163-171.
  • Wildin RS, Smyk-Pearson S, Filipovich AH. 2002. Clinical and molecularfeatures of theimmunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J MedGenet, 39:537-545.
  • Engin A, Arslan S, Kizildag S, Ozturk H, Elaldi N, Dokmetas I, Bakir M. 2010. Tool-likereceptor 8 and 9 polymorphisms in Crimean-Congohemorrhagicfever. Microbes and Infection, 12:1071-1078.
  • Hanel SA, Velavan TP, Kremsner PG, Kun JF. 2011. Novel and functionalregulatorySNPs in thepromoterregion of Foxp3 gene in a Gabonesepopulation. Immunogenetics, 63:409-415.
  • Bassuny WM, Ihara K, Sasaki Y, Kuromaru R, Kohno H, Matsuura N, Hata T. 2003. A functionalpolymorphism in thepromoter/enhancerregion of theFoxp3/Scurfin gene associatedwithtype 1 diabetes. Immunogenetics, 55:149-156.
  • Ullrich A, Shine J, Chirgwin J, et al. 1997. Rat insülin genes: construction of plasmidscontainingthecodingsequences. Science, 196(4296):1313-1319.
  • Geisbert TW, Jahrling PB. 2004. Exoticemerging viral diseases: progress and challenges. NatMed, 10:110-121.
  • Singer BD, King LS, D’Alessio FR. 2014. Regulatory T cells as immunotherapy. Front Immunol, 5:46.
  • Lund JM, Hsing L, Pham TT, Rudensky AY. 2008. Coordination of earlyprotectiveimmunityto viral infectionbyregulatory T cells. Science, 320(5880):1220-1224.
  • Swanepoel R, Gill DE, ShepherdAj, Leman PA, Mynhardt JH, Harvey S. 1989. Theclinicalpathology of Crimean-Congohaemorrahagicfever. RevInfectDis, 4:794-800.
  • Sun L, Wu J and Yi S. 2012. Foxp3 is criticalforhumannatural CD4+CD25+ regulatory T cellstosuppressalloimmuneresponse. TransplImmunol, 26:71-80.
  • Kaya S, Elaldi N, Kubar A, Gursoy N, Yilmaz M, Karakus G, Gunes T, Polat Z, Gozel MG, Engin A, Dokmetas I, Bakir M, Yilmaz N, Sencan M. 2014. Sequentialdetermination of serum viral titers, virüs-specificIgGantibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patientswithCrimean-Congohemorrhagicfever. BMC InfectDis, 14:416.
  • Yilmaz M, Elaldi N, Bagci B, Sari I, Gumus E, Yelkovan I. 2015. Effect of tumournecrosisfactor-alpha and interleukin-6 promoterpolymorphisms on course of Crimean-Congohemorrhagicfever in Turkishpatients. J VectorBorneDis, 52:30-35.
  • Akinci E, Bodur H, Leblebicioglu H. 2013. Pathogenesis of Crimean-Congohemorrhagicfever. VectorBorneZoonoticDis, 13:429-437.

Year 2018, Volume: 12 Issue: 2, 25 - 27, 25.09.2018

Ergun Pinarbasi Nilgun Cekin Aslihan Esra Bildirici Mehmet Bakir Serdal Arslan

Abstract

References

  • Elaldı N. 2004. Kırım-Kongo hemorajik ateş epidemiyolojisi. C.Ü. Tıp Fakültesi Dergisi, 26(4):185-190.
  • Ergonul O. 2006. Crimean-Congohaemorrhagicfever. LancetInfect. Dis.,6:203-214.
  • Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, Carroll MW. 2014. A novelvaccineagainstCrimean-Congohaemorrhagicfeverprotects 100% of animalsagainstlethalchallenge in a Mouse model. PlosOne, 9(3):e91516.
  • Leblebicioglu H, Ozaras R, Irmak H, Sencan I. 2016. Crimean-Congohaemorrhagicfever in Turkey: Currentstatus and futurechallenges. Antiviral Research, 126:21-34.
  • Ministry of Health, Turkey. Reports of thecommunicablediseasesdepartment (2008) Ankara (Turkey) (in Turkish). Available at: http://www.saglik.gov.tr
  • Ozkurt Z. 2007. Kırım-Kongo kanamalı ateşi. Yoğun Bakım Dergisi, 7(1):85-90.
  • Elaldi N, Kaya S. 2014. Crimean-Congohaemorrhagicfever. JMID, 1:1-9.
  • Esen F. 2008. CD4+T hücrelerinde güncel gelişmeler: Th17 hücreleri. Cerrahpaşa Öğrenci Bilimsel Dergisi, 1(1).
  • Weaver CT, Harrington LE, Mangan PR, Gavrielli M, Murphy KM. 2006. Th17: An effector CD4 T celllineagewithregulatory T cellties. Immunity, 24:677-688.
  • Oda JMM, Hirata BKB, Guembarovski RL, Watanabe MAE. 2013. Geneticpolymorphism in Foxp3 gene: imbalance in regulatory T cell role and development of humandiseases. J Genet.,92:163-171.
  • Wildin RS, Smyk-Pearson S, Filipovich AH. 2002. Clinical and molecularfeatures of theimmunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J MedGenet, 39:537-545.
  • Engin A, Arslan S, Kizildag S, Ozturk H, Elaldi N, Dokmetas I, Bakir M. 2010. Tool-likereceptor 8 and 9 polymorphisms in Crimean-Congohemorrhagicfever. Microbes and Infection, 12:1071-1078.
  • Hanel SA, Velavan TP, Kremsner PG, Kun JF. 2011. Novel and functionalregulatorySNPs in thepromoterregion of Foxp3 gene in a Gabonesepopulation. Immunogenetics, 63:409-415.
  • Bassuny WM, Ihara K, Sasaki Y, Kuromaru R, Kohno H, Matsuura N, Hata T. 2003. A functionalpolymorphism in thepromoter/enhancerregion of theFoxp3/Scurfin gene associatedwithtype 1 diabetes. Immunogenetics, 55:149-156.
  • Ullrich A, Shine J, Chirgwin J, et al. 1997. Rat insülin genes: construction of plasmidscontainingthecodingsequences. Science, 196(4296):1313-1319.
  • Geisbert TW, Jahrling PB. 2004. Exoticemerging viral diseases: progress and challenges. NatMed, 10:110-121.
  • Singer BD, King LS, D’Alessio FR. 2014. Regulatory T cells as immunotherapy. Front Immunol, 5:46.
  • Lund JM, Hsing L, Pham TT, Rudensky AY. 2008. Coordination of earlyprotectiveimmunityto viral infectionbyregulatory T cells. Science, 320(5880):1220-1224.
  • Swanepoel R, Gill DE, ShepherdAj, Leman PA, Mynhardt JH, Harvey S. 1989. Theclinicalpathology of Crimean-Congohaemorrahagicfever. RevInfectDis, 4:794-800.
  • Sun L, Wu J and Yi S. 2012. Foxp3 is criticalforhumannatural CD4+CD25+ regulatory T cellstosuppressalloimmuneresponse. TransplImmunol, 26:71-80.
  • Kaya S, Elaldi N, Kubar A, Gursoy N, Yilmaz M, Karakus G, Gunes T, Polat Z, Gozel MG, Engin A, Dokmetas I, Bakir M, Yilmaz N, Sencan M. 2014. Sequentialdetermination of serum viral titers, virüs-specificIgGantibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patientswithCrimean-Congohemorrhagicfever. BMC InfectDis, 14:416.
  • Yilmaz M, Elaldi N, Bagci B, Sari I, Gumus E, Yelkovan I. 2015. Effect of tumournecrosisfactor-alpha and interleukin-6 promoterpolymorphisms on course of Crimean-Congohemorrhagicfever in Turkishpatients. J VectorBorneDis, 52:30-35.
  • Akinci E, Bodur H, Leblebicioglu H. 2013. Pathogenesis of Crimean-Congohemorrhagicfever. VectorBorneZoonoticDis, 13:429-437.
There are 23 citations in total.

Details

Primary Language English
Journal Section Research Article
Authors

Ergun Pinarbasi

Nilgun Cekin This is me

Aslihan Esra Bildirici This is me

Mehmet Bakir This is me

Serdal Arslan This is me

Publication Date September 25, 2018
Published in Issue Year 2018 Volume: 12 Issue: 2

Cite

APA Pinarbasi, E., Cekin, N., Bildirici, A. E., Bakir, M., et al. (2018). No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. Journal of Applied Biological Sciences, 12(2), 25-27.
AMA Pinarbasi E, Cekin N, Bildirici AE, Bakir M, Arslan S. No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. J.appl.biol.sci. September 2018;12(2):25-27.
Chicago Pinarbasi, Ergun, Nilgun Cekin, Aslihan Esra Bildirici, Mehmet Bakir, and Serdal Arslan. “No Association Between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease”. Journal of Applied Biological Sciences 12, no. 2 (September 2018): 25-27.
EndNote Pinarbasi E, Cekin N, Bildirici AE, Bakir M, Arslan S (September 1, 2018) No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. Journal of Applied Biological Sciences 12 2 25–27.
IEEE E. Pinarbasi, N. Cekin, A. E. Bildirici, M. Bakir, and S. Arslan, “No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease”, J.appl.biol.sci., vol. 12, no. 2, pp. 25–27, 2018.
ISNAD Pinarbasi, Ergun et al. “No Association Between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease”. Journal of Applied Biological Sciences 12/2 (September 2018), 25-27.
JAMA Pinarbasi E, Cekin N, Bildirici AE, Bakir M, Arslan S. No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. J.appl.biol.sci. 2018;12:25–27.
MLA Pinarbasi, Ergun et al. “No Association Between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease”. Journal of Applied Biological Sciences, vol. 12, no. 2, 2018, pp. 25-27.
Vancouver Pinarbasi E, Cekin N, Bildirici AE, Bakir M, Arslan S. No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. J.appl.biol.sci. 2018;12(2):25-7.